Kornimate/medical-research-clean huggingface dataset:
written exposure in substance treatment

Conditions: Posttraumatic Stress Disorder; Substance Use Disorders

Summary: the purpose of this pilot randomized clinical trial is to test the feasibility and efficacy of written exposure therapy (wet) for posttraumatic stress disorder (ptsd) within the context of residential substance use disorder (sud) treatment. all participants meet criteria for ptsd and are in a short term residential sud treatment program (target residential treatment duration = 28 days) regardless of the research. the main questions the study aims to answer are: 1) is the delivery of wet feasible in short term residential sud treatment for individuals with severe sud; 2) do participants in the tau+wet condition have greater reductions in ptsd symptoms pre/post treatment compared to participants in tau alone?


Eligibility criteria:
inclusion criteria: * at least 18 years old * fluent in english * cognitively able to provide consent to the research * enrolled in inpatient treatment at the clinical site where the research takes place * meet criteria for probable ptsd based on pcl-5 score * be early enough in their residential stay to allow time to complete the wet protocol * have a clear memory of the traumatic event so they are able to write about itin detail exclusion criteria: * reports significant suicidal or homicidal ideation with intent, untreated psychosis, or have other health limitations that may interfere with their ability to participate in the research

Keywords: written exposure therapy
development and feasibility testing of dm-boost intervention.

Conditions: Diabetes Mellitus, Type 2

Summary: dm-boost uses clinical informatics tools to identify types of patients with gaps in diabetes care and deploy tailored, proactive outreach methods rooted in behavioral economics to nudge them towards increased engagement with diabetes self-management training and leverage patient-facing technologies to enhance longitudinal patient self-management support.

in dm-boost, the principal investigator will deploy a mixed-methods, patient-centered approach to intervention development and initiate a multiphase optimization strategy (most) to learn how to maximize patient engagement and support of self-management training. in this pilot, study team will complete the first phase (preparation), and initiate feasibility piloting of the second phase (optimization). completion of optimization and most's final phase (evaluation), will occur in a subsequent project. in the preparation phase, principal investigator will first analyze ehr and claims data in the umccts data lake to identify sociodemographic characteristics associated with gaps in diabetes care to develop patient persona archetypes (aim 1). next, principal investigator will selectively recruit patients of identified persona types as consultants, elicit stakeholder feedback during community engagement studios and conduct usability testing to iteratively design the intervention (aim 2). study team will then conduct a feasibility pilot (aim 3) to assess user experience of the intervention implementation and collect exploratory outcome data to be used to inform a subsequent, complete optimization trial.

Eligibility criteria:
inclusion criteria: * adults (age 18+) * cognitively able to consent (aims 2 and 3) * diagnosed with type 2 diabetes (aims 1-3) * receive primary care at ummhc in past 12 months at time of initial analysis (aims 1-3) * english speaking (aims 2 and 3) * have access to patient portal or a smart phone (aim 3) exclusion criteria: * adults unable to consent (lacking cognitive capacity) (aims 2 and 3) * individuals who are not yet adults (infants, children, teenagers) (aims 1-3) * pregnant women (aims 1-3) * prisoners (aims 1-3) * non-english speaking (aims 2 and 3)
optimization of keverprazan-amoxicilli dual therapy for helicobacter pylori

Conditions: H. Pylori Infection

Summary: the purpose of this study was to evaluate the efficacy and safety of keverprazan with different doses of amoxicillin for helicobacter pylori.

this study is a prospective, single-center, open-label, randomized, parallel-controlled trial. a total of 268 h. pylori positive patients needed to be recruited and were randomized into 2 groups in 1:1 ratio, group a was the control group and subjects were required to take keverprazan 20mg,bid and amoxicillin 1.0g,tid for 14 days. group b was the experimental group and subjects were required to take keverprazan 20mg,bid and amoxicillin 1.0g,tid for 14 days. all the above regimens were used for eradication of h. pylori. during the 14-day eradication treatment, all subjects were instructed and asked to record their adverse drug reactions and compliance. on days 7 and 14 of treatment, researchers followed up with patients via wechat or phone to determine adverse reactions and compliance, and observed and recorded whether subjects experienced any adverse reactions such as nausea, diarrhea, dizziness, bitter taste in the mouth, rash, and constipation. subjects were seen again 4 weeks after the end of treatment to check for h. pylori eradication by 13c-ubt or 14c-ubt. patients were encouraged, but not required, to undergo tongue and fecal flora testing before and after h. pylori eradication to determine the short-term effects of different doses of amoxicillin in combination with keverprazan for 14 days on the patient's tongue and intestinal flora.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with helicobacter pylori positivity through 13c-ubt or 14c-ubt 2. patients who have not received eradication treatment for helicobacter pylori in the past, or who have failed eradication in the early stage but have not received eradication treatment within six months 3. voluntarily participate in this experiment and sign an informed consent form exclusion criteria: 1. allergies to research drugs (such as those allergic to penicillin, amoxicillin, keverprazan) 2. patients with peptic ulcer 3. patients who have received helicobacter pylori eradication treatment within six months 4. use antibiotics or bismuth medication 4 weeks before starting the study；use p-cab or ppi 2 weeks before starting the study 5. using corticosteroids, non steroidal anti-inflammatory drugs, or anticoagulants 6. those who are using atazanavir, nelfinavir, rilpivirine, itraconazole, tyrosine kinase inhibitors (imatinib, gefitinib, etc.), digoxin, and methyl digoxin 7. history of esophageal or gastric surgery 8. pregnant or lactating women 9. suffering from serious concomitant diseases such as liver disease, cardiovascular disease, lung disease, or kidney disease 10. excessive drinking 11. gastric mucosa-associated lymphoid tissue lymphoma (malt), malignant neoplastic diseases
efficacy and safety evaluation of sintilimab in combination with ibi310 as treatment in patients with ebv-positive gastric cancer

Conditions: Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of sintilimab+ ibi310 for ebv-positive advanced gastric or gastroesophageal junction (gej) adenocarcinoma.


Eligibility criteria:
inclusion criteria: * has histologically confirmed diagnosis of unresectable locally advanced,recurrent or metastatic gastric or gej malignant tumor (including squamous carcinoma, adenocarcinoma, signet-ring cell carcinoma). * confirmed ebv positive determined by in situ hybridization (ish), analyzed with tumor tissue sample, either from a previous surgery or biopsy , within last 6 months * male or female at least 18 years of age * has an eastern cooperative oncology group (ecog) performance status of 0 or 1 * has adequate organ function. * expected survival\>=12 weeks * women of childbearing potential (wocbp) must have a negative urine or serum pregnancy test at the timing of enrollment. * participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 6 months after the last dose of study medication. applied to arms 1: has histologically confirmed gastric/gej malignant tumor, and were regarded as having clinical stage t3-t4an0m0 or t2～4an+m0 applied to arms 2: had no prior systemic treatment for metastatic disease. applied to arms 3: received ≥1 prior systemic treatment for metastatic disease. exclusion criteria: * has received prior therapy with an anti-programmed death (pd)-1, antipd-l1, anti-pd l2, anti-ctla-4 agent or with an agent directed to another stimulatory or co-inhibitory t-cell receptor * is currently participating in and receiving study therapy ,except those in the survival follow up period of an investigational agent study or non-interventional study . * received systemic treatment with corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 4 weeks of first dose. inhaled or topical steroids ,adrenal replacement steroid doses and steroid of prevention allergic reaction of i.v. contrast agent are permitted in the absence of active autoimmune disease. * received a live vaccine within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period. * has had major surgery (craniotomy, thoracotomy or laparotomy) within 4 weeks prior to first dose of study medication, or anticipation of the need for major surgery during the course of study treatment
a long-term extension study to evaluate safety, tolerability, and efficacy of al002 in alzheimer's disease

Conditions: Alzheimer's Disease

Summary: a long-term extension study to evaluate the safety, tolerability, and efficacy of al002 in participants with early alzheimer's disease.

this is a phase 2, parallel-group, long-term extension (lte), dose-blind study to evaluate the long-term safety and efficacy of al002 in participants with early alzheimer's disease. the study is a multicenter, global trial that will enroll participants who completed the planned treatment period in al002-2 (parent study).

Eligibility criteria:
inclusion criteria: * completion of the planned treatment period in the al002-2 study. * the participant is willing and able to give informed consent. * study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week exclusion criteria: * participants deemed not able to provide consent or assent by the investigator or by local regulations. * participants who were prematurely and permanently discontinued from treatment in the parent study for safety reasons. * participation deemed inappropriate per investigator discretion.
a study to evaluate pf-00915275 in subjects with type 2 diabetes mellitus for 4-weeks

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of pf-00915275 following administration to adult human subjects with t2dm for 4-weeks. the primary end point is glucose lowering (24 hour mean glucose concentration).


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * hba1c \> 7.5%. exclusion criteria: * recent (within the past 12 months) evidence or history of unstable concomitant disease. * treatment with any oral hypoglycemic agent within 3 months before enrollment. * the exception to these criteria is that subjects who are currently taking metformin hydrochloride, in a stable dose (that is no changes in dose) for treatment of their diabetes within the past 3 months or longer of enrollment may participate.
metabolomics and microbiomics in cardiovascular diseases

Conditions: Acute Heart Failure; NSTEMI - Non-ST Segment Elevation MI; STEMI - ST Elevation Myocardial Infarction; Myocardial Infarction, Acute; Sepsis; Cardiomyopathies; Dilated Cardiomyopathy; Ischemic Cardiomyopathy

Summary: "metabolomics and microbiomics in cardiovascular diseases mannheim (memoriam) " is a single-center, prospective and observational study investigating to identify disease-specific metabolic, respectively microbiomic, patterns of patients with high-risk cardiovascular diseases. high-risk cardiovascular diseases comprise patients suffering from acute heart failure (ahf), st-segment elevation myocardial infarction (stemi), non-st-segment elevation myocardial infarction (nstemi), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy.

scientific evidence about the metabolomic and microbiomic changes in high-risk cardiovascular patients is still lacking. the acute, critical or progressive disease status predestinies to relevant changes in cardiovascular metobolism. high-risk patients in the present trial comprise those with acute heart failure, myocardial infarction (stemi and nstemi), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy with severely reduced left ventricular ejection fraction (lvef \<35%). therfore this study investigates to identify disease-specific patterns of metabolic and microbiomic changes. these patterns may help to understand pathophysiology at the metabolic stages and find out those patients being at highest risk of adverse future outcome.

Eligibility criteria:
inclusion criteria: * above mentioned diseases, diagnosis according to respective guideline * written informed consent exclusion criteria: * under 18 years * cancer * rheumatic diseases * infections (except septic group) * higher grade heart valve diseases
motion analysis of sit-to-stand movements in children with spastic diplegia

Conditions: Cerebral Palsy

Summary: the purpose of this study is to compare movement variations before and after the loaded training, with kinematics, kinetics, and electromyography, in children with spastic diplegia and to further discuss mechanisms of the loaded training.

subjects: this study will recruit twenty children who are aged between 5 and 12 years, with spastic diplegia, and without having major surgeries or botulinum toxin injection on lower extremities during the past 6 months prior to participate in this study. methods: the vicon 250 motion analysis system, 3 amti force platforms and the emg recording system will be used to collect data of sit-to-stand (sts) movements. baseline, pre- and post-training evaluations will be carried out. the duration of the baseline and pre-training evaluations is 2 months. the training period will take about 6 weeks. each evaluation will take two separate days to accomplish. on the first day, the sts1rm of individual children was determined. on the second day, kinematic and kinetic data of sts movements in natural and loaded (applying load of 50% sts1rm during sts movements) conditions were collected. data of smoothness, maximal extension moment and around hip and knee joints, onset time of lower extremity muscles will then be calculated. results of each evaluation will be used for further comparison.

Eligibility criteria:
inclusion criteria: * diagnosed as spastic diplegia * aged between 5 and 12 years * able to perform the sts movements without assistance * able to cooperate and understand commands given exclusion criteria: * severe musculoskeletal deformity or pain on lower extremities * botulism injection in the past 3 months or major operations in the preceding 6 months on lower extremities * uncontrolled epilepsy * major sensory deficits, such as blindness or deafness

Keywords: cerebral palsy resistance movement biomechanics
third ward wellness study for families

Conditions: Child Obesity

Summary: the third ward wellness study aims to pilot test a wellness program for families with toddler age children. participants will be recruited from the third ward neighborhood in houston, tx and then randomly assigned to one of two wellness programs. the goal of both programs is to enable and inspire parents to help their toddler age children develop healthy habits that will stay with them through life. participating families will complete an assessment batter before and after the program. both programs will meet once per week for 10 weeks.

dietary and activity habits begin to develop in early childhood. parents have the most influence on children's health behaviors at this age. many parents, particularly those from lower income and underserved areas may benefit from programs to inspire and enable them to raise their toddler age children with good health habits. the experimental group was developed to help parents instill healthy habits in their children through a healthy home environment. this study will pilot test the experimental group among parent-toddler dyads residing in greater third ward neighborhoods, where \> 80% of the residents are aa or hispanic and 35%-54% have annual household incomes \<$25,000. the aims are to ascertain 1) recruitment and retention barriers and facilitators, 2) treatment success barriers and facilitators, and 3) the estimated effect sizes of outcomes to inform a fully powered rct. the exploratory hypotheses are that compared to those in the control group, parents in the experimental group will have greater increases in positive parenting skills (comprehensive general parenting questionnaire), and toddlers will have greater increases in indicators of a healthy home environments, diets and activity habits (mvpa, sedentary activity, and sleep).

Eligibility criteria:
inclusion criteria: parents need to be... * the legal custodian of a toddler, * at least 18 years, * able to make food decisions in the home, * have access to a phone at home, * be fluent in english toddlers need to be... * between 12 and 36 months of age * be able to walk. exclusion criteria: * adults unable to consent for themselves and their child, * parents or toddlers who have mental or physical health conditions that would prevent them from fully engaging in activities of the program (e.g., reliance on feeding tube).
radiotherapy for thoracic and breast cancer and the related cardiotoxicity following treatment (raccoon)

Conditions: Patients Who Receive Thoracic Irradiation

Summary: the purpose of this study is to investigate the risk factors and mechanisms of cardiotoxicity following thoracic radiotherapy and to provide insights in preventing radiation-related cardiotoxicity. -condition or disease : thoracic irradiation -intervention/treatment : cardiac evaluation, blood sampling

cancer patients who undergo thoracic irradiation receive a certain amount of dose to the heart. cardiotoxicity may occur in some patients several years after radiotherapy due to the late effect of radiation. considering that cardiotoxicity is often lethal, screening and preventing radiation-induced cardiotoxicity is crucial in patients receiving thoracic irradiation. patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation. the dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in ct images. dose-volume parameters that predict cardiotoxicity will be analyzed. among the patients who developed cardiotoxicity, blood sampling will be performed to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets.

Eligibility criteria:
inclusion criteria: 1. patients with solid cancer who are subject to thoracic irradiation. 2. patients who are 20 years old or older 3. eastern cooperative oncology group performance status scale 0-2 4. patients with cognitive abilities to receive virtual reality information exclusion criteria: 1. patients with a history of previous thoracic irradiation 2. patients who refused consent 3. patients with a history of heart failure before radiotherapy
hyperbaric oxygen therapy improves brain function in patients with cognitive decline after covid-19 infection.

Conditions: Cognitive Decline; COVID-19; SARS CoV 2 Infection

Summary: covid-19 has swept the world, and while some people may experience long-term cognitive decline as a result of infection, no effective treatment has been announced. the primary goal of this study was to determine the efficacy of hyperbaric oxygen therapy in patients with sars-cov-2 infection, as well as to assess the effect of hyperbaric oxygen therapy on brain function in patients with covid-19-related cognitive decline. in this study, approximately 80 people were randomly assigned to either hyperbaric oxygen or regular oxygen therapy to compare the effects of these two treatments on disease.

80 patients with cognitive impairment following a novel coronavirus infection will be randomly assigned to one of two treatment groups: hyperbaric oxygen therapy or conventional oxygen therapy. after the intervention, the improvement of hyperbaric oxygen on cognition, fatigue, sleep disorders, anxiety and depression, and other clinical manifestations was observed. the neurologic function of hyperbaric oxygen in the treatment of patients with cognitive decline after sars-cov-2 infection was also evaluated from imaging and electrophysiological multi-dimensional indexes.

Eligibility criteria:
inclusion criteria: * out-patients 4 weeks after the diagnosis of sars-cov-2 infection * subjective cognitive decline after sars-cov-2 infection * sars-cov-2 nucleic acid/antigen test negative. exclusion criteria: * contraindications to hyperbaric oxygen therapy * cognitive decline can be explained by other diseases * conditions that researchers consider unsuitable for clinical trials.
iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing coronary angiography and/or intervention

Conditions: Renal Insufficiency, Chronic; Coronary Angiography; Angioplasty, Transluminal, Percutaneous Coronary

Summary: the prevention of contrast-mediated nephropathy (cmn), which accounts for considerable morbidity and mortality, remains a vexing problem. contrast induced renal vasoconstriction is believed to play a pivotal role in the cmn mechanism. the aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing cmn in high-risk patients undergoing a coronary procedure.


Eligibility criteria:
inclusion criteria: * patients undergoing clinically driven, non-emergent coronary angiography or intervention in our institution were eligible for inclusion if their serum creatinine concentration was ≥1.4 mg/dl (124 μmol/l) and/or their creatinine clearance was \<60 ml/min on their most recent sample drawn within 1 month of the planned procedure exclusion criteria: * circulatory shock for any reason, systolic blood pressure \<95 mm hg * known acute renal failure * end-stage renal disease requiring dialysis * intravascular administration of a contrast medium within the previous 10 days * anticipated re-administration of contrast medium within the following 6 days * inability to administer intravenous hydration at least 4 h before the procedure or study medication at least 30 min before the procedure * primary intervention for acute infarction with st elevation * a procedure performed within 2 h of acute hospital admission

Keywords: contrast media contrast nephropathy